F. Fossella

发表

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

A. Ardizzoni, L. Boni, M. Tiseo, 2007, Journal of the National Cancer Institute.

Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: Evidence from a pooled analysis of 2,838 patients randomized in 7 trials

M. Buyse, V. Georgoulias, F. Fossella, 2008 .

The BATTLE trial: personalizing therapy for lung cancer.

Edward S. Kim, S. Lippman, F. Khuri, 2011, Cancer discovery.

Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.

Edward S. Kim, Diane D. Liu, I. Wistuba, 2017, The Annals of thoracic surgery.

Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.

I. Wistuba, S. Swisher, J. Heymach, 2019, Journal of Clinical Oncology.

P2.04-90 Nodal Immune Flare (NIF) Following Neoadjuvant Anti-PD-1 and Anti-CTLA-4 Therapy in Non-Small Cell Lung Cancer

S. Swisher, J. Heymach, M. Godoy, 2019, Journal of Thoracic Oncology.

Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial

Michael Peyton, John D. Minna, Lixia Diao, 2013, Clinical Cancer Research.

Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.

A. Garden, W. Hong, J. Roth, 1995, International journal of radiation oncology, biology, physics.

Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.

Joe Y. Chang, Xiaodong Zhang, Steven H. Lin, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer.

Joe Y. Chang, P. Thall, D. Gomez, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.

J. Lee, R. Komaki, J. Kurie, 2003, Clinical lung cancer.

Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors.

S. Lippman, W. Hong, F. Fossella, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): P2-328

G. Scagliotti, Keunchil Park, U. Gatzemeier, 2007 .

PHASE I/II STUDY OF GEMCITABINE, AN ACTIVE AGENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

S. Lippman, F. Fossella, P. Tarasaoff, 1995 .

Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.

F. Khuri, W. Hong, R. Herbst, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).

K. Coombes, J. Lee, W. Hong, 2013 .

Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection.

Joe Y. Chang, T. Guerrero, J. Roth, 2004, International journal of radiation oncology, biology, physics.

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.

R. A. Robinson, S. Lippman, J. Lee, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma

W. Hong, I. Wistuba, J. Lee, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Second line chemotherapy for NSCLC: establishing a gold standard.

F. Shepherd, F. Fossella, T. Lynch, 2002, Lung cancer.

Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.

F. Khuri, C. Stevens, R. Komaki, 2002, Seminars in radiation oncology.

Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma

A. Tolcher, F. Fossella, K. Berg, 2005 .

Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma

A. Tolcher, P. Fidias, F. Fossella, 2007 .

Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)".

S. Lippman, J. Roth, S. Swisher, 2008, Chest.

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

F. Fossella, P. Lorigan, P. Woll, 2016, Investigational New Drugs.

Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials.

F. Fossella, 1999, Seminars in oncology.

Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

R. Govindan, D. Carbone, P. Fidias, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC)

F. Fossella, M. Millward, J. Bérille, 2000 .

Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery.

J. Roth, C. Stevens, J. Cox, 2003, International journal of radiation oncology, biology, physics.

CISCA (cisplatin vs. carboplatin) meta-analysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC).

A. Ardizzoni, L. Boni, M. Tiseo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer as Frontline and Second-Line Therapy

Edward S. Kim, S. Lippman, F. Khuri, 2009, American journal of clinical oncology.

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer.

R. Herbst, F. Fossella, G. Blumenschein, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

Diane D. Liu, J. Lee, R. Herbst, 2003, Lung cancer.

Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program.

Diane D. Liu, J. Lee, R. Herbst, 2006, Clinical lung cancer.

Phase I study of farnesyl tranferase inhibitors (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety

P. Thall, F. Khuri, W. Hong, 2000 .

Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone.

Joe Y. Chang, T. Guerrero, R. Herbst, 2007, International journal of radiation oncology, biology, physics.

High Mutagen Sensitivity in Peripheral Blood Lymphocytes Predicts Poor Overall and Disease-Specific Survival in Patients with Stage III Non–Small Cell Lung Cancer Treated with Radiotherapy and Chemotherapy

Joe Y. Chang, M. Spitz, Xifeng Wu, 2005, Clinical Cancer Research.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Miklos Pless, N. Hanna, C. Desch, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy in Previously Treated Patients with Non-small Cell Lung Cancer

F. Fossella, 2010 .

Many Patients 80 Years and Older with Advanced Non-small Cell Lung Cancer (NSCLC) Can Tolerate Chemotherapy

G. Ayers, F. Fossella, Wei Wei, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

6521 POSTER Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC)

G. Scagliotti, Keunchil Park, U. Gatzemeier, 2007 .

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Edward S. Kim, W. R. Bishop, P. Thall, 2004, Clinical Cancer Research.

Management strategies for recurrent non-small cell lung cancer.

F. Fossella, J. Lee, W. Hong, 1997, Seminars in oncology.

Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials.

M. Kris, J. Rigas, F. Shepherd, 2001, Seminars in oncology.

Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.

W. Hong, J. Roth, S. Swisher, 1998, Seminars in oncology.

IClinicalTrial ofThoracic Radiotherapy and Concurrent Celecoxib for Patientswith Unfavorable Performance Status Inoperable / Unresectable Non ^ Small Cell Lung Cancer

Joe Y. Chang, T. Guerrero, R. Komaki, 2005 .

Emerging therapies in non-small-cell lung cancer.

F. Khuri, R. Herbst, F. Fossella, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists.

E. Bruera, J. Cortes, F. Fossella, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma.

J. Ajani, J. Roth, R. Komaki, 1991, International journal of radiation oncology, biology, physics.

O-51 Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCB) versus vinorelbine-cisplatin (VC) for the first-line treatment of advanced/metastatic non-small cell lung cancer (NSCLC): analyses in elderly patients

F. Fossella, C. Belani, 2003 .

Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.

J. Roth, I. Wistuba, J. Lee, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report.

Edward S. Kim, F. Khuri, W. Hong, 2004, Lung cancer.

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.

J. Heymach, A. Tsao, L. Byers, 2022, Cancer cell.

NCCN Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network.

G. Demetri, F. Fossella, D. Gershenson, 1996, Oncology.

Pattern and Predictors of Outpatient Palliative Care Referral Among Thoracic Medical Oncologists

Diane D. Liu, E. Bruera, F. Fossella, 2018, The oncologist.

Objective evaluation of physical function in patients with advanced lung cancer: a preliminary report.

E. Bruera, M. Simmonds, F. Fossella, 2006, Journal of Palliative Medicine.

Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer.

F. Fossella, J. Bérille, J. Lee, 1995, Seminars in oncology.

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.

W. Hong, R. Perez-soler, F. Fossella, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

N. Ajami, J. Roth, I. Wistuba, 2021, Nature Medicine.

HighMutagen Sensitivity in Peripheral Blood Lymphocytes Predicts Poor Overall and Disease-Specific Survival in Patients with Stage IIINon^Small Cell Lung Cancer Treatedwith Radiotherapy and Chemotherapy

Joe Y. Chang, M. Spitz, C. Stevens, 2005 .

Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial.

E. Bruera, G. Eapen, A. Tsao, 2016, Journal of pain and symptom management.

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

I. Wistuba, J. Heymach, K. Kelly, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Preliminary results

K. Kelly, F. Fossella, J. Schiller, 2004 .

Docetaxel for previously treated non-small-cell lung cancer.

F. Fossella, 2002, Oncology.

Pemetrexed for treatment of advanced non-small cell lung cancer.

F. Fossella, 2004, Seminars in oncology.

Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma

W. Hong, R. Winn, F. Fossella, 1992, Investigational New Drugs.

Impact of Checkpoint Inhibitor Immunotherapy Primarily Pembrolizumab on Infection Risk in Patients with Advanced Lung Cancer: A Comparative Retrospective Cohort Study.

F. Fossella, D. Kontoyiannis, Patrick Chaftari, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial.

Joe Y. Chang, E. Bruera, S. Shete, 2022, The Lancet. Oncology.

Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer.

S. Lippman, W. Hong, H. Libshitz, 1992, Journal of the National Cancer Institute.

Toxicity and Survival after Intensity-Modulated Proton Therapy (IMPT) versus Passive Scattering Proton Therapy (PSPT) for Non-Small Cell Lung Cancer.

Joe Y. Chang, Steven H. Lin, X. Zhu, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial

W. Curran, H. Choy, R. Komaki, 2008 .

Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.

F. Fossella, 1999, Seminars in oncology.

Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.

F. Khuri, W. Hong, J. Roth, 1999, Journal of the National Cancer Institute.

Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.

R. Mohan, Xiaodong Zhang, D. Gomez, 2017, International journal of radiation oncology, biology, physics.

Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC).

J. Lee, S. Swisher, J. Heymach, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine (G) with concurrent chest radiation (XRT) followed by consolidation chemotherapy with gemcitabine plus cisplatin (CDDP): A phase I trial for patients with stage III non-small cell lung cancer (NSCLC)

F. Khuri, W. Hong, R. Herbst, 2000 .

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

J. Roth, R. Komaki, E. Atkinson, 1994, Journal of the National Cancer Institute.

Single-agent docetaxel in patients with refractory non-small-cell lung cancer

F. Fossella, 1997 .

Phase I study of paclitaxel administered by ten-day continuous infusion

S. Lippman, R. Perez-soler, J. Kurie, 1998, Investigational New Drugs.

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

L B Sheiner, A Riva, P M Ravdin, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer

Diane D. Liu, F. Khuri, W. Hong, 2000 .

Characterization and identification of specific EGFR mutations in circulating tumor cells (CTCs) isolated from non-small cell lung cancer patients using antibody independent method, ApoStream.

A. Tsao, F. Fossella, V. Papadimitrakopoulou, 2013 .

High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: results of a phase II trial.

Joe Y. Chang, J. Welsh, Ying Yuan, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial.

Joe Y. Chang, Steven H. Lin, Z. Liao, 2022, Lung cancer.

Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.

R. Herbst, C. Stevens, R. Komaki, 2004, International journal of radiation oncology, biology, physics.

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

M. Kris, D. Gandara, V. Miller, 2000 .

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.

U. Gatzemeier, F. Fossella, M. Reck, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small cell lung cancer.

Renato Martins, Nithya Ramnath, Bruce E Johnson, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.

R. Herbst, B. Sabloff, K. Pisters, 2004, Lung cancer.

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

R. Ramlau, J. von Pawel, J. R. Pereira, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.

G. Scagliotti, N. Hanna, F. Shepherd, 2009, The oncologist.

Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial

A. Tsao, D. Gibbons, F. Fossella, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ZD1839 (Iressa TM ) In Non-Small-Cell Lung Cancer

F. Khuri, R. Herbst, K. Pisters, 2001 .

Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.

Radhe Mohan, Stephen M Hahn, John V Heymach, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive Biomarkers and Personalized Medicine Comprehensive Biomarker Analysis and Final Ef fi cacy Results of Sorafenib in the BATTLE Trial

Edward S. Kim, Jing Wang, J. Minna, 2013 .

Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.

S. Lippman, R. Perez-soler, F. Fossella, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non–Small Cell Lung Cancer

F. Fossella, E. Waxman, 2016, Journal of the advanced practitioner in oncology.

Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.

J. Bayouth, F. Fossella, D. Macey, 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.

F. Khuri, J. Roth, J. Lee, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer

G. Scagliotti, F. Shepherd, J. Vansteenkiste, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Docetaxel for treatment of solid tumours: a systematic review of clinical data.

G. Hortobagyi, V. Valero, F. Fossella, 2005, The Lancet. Oncology.

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma

W. Hong, F. Fossella, G. Walsh, 1995, Cancer.

Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.

D. Nyberg, R. Perez-soler, J. Kurie, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.

Li Shen, John V Heymach, Kevin R Coombes, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma

F. Fossella, G. Blumenschein, D. Karp, 2010, Cancer.

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

M. Kris, D. Gandara, E. Vokes, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.

R. Winn, F. Fossella, D. Shin, 1993, Journal of the National Cancer Institute.

Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.

P. Fidias, R. Ramlau, J. von Pawel, 2006, Lung cancer.

Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer

Edward S. Kim, C. Obasaju, G. Gladish, 2005, Cancer.

Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non‐small cell lung cancer

S. Lippman, H. Libshitz, F. Fossella, 1991, Cancer.

The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma

Diane D. Liu, F. Khuri, J. Lee, 2002, Cancer.

Second–line chemotherapy for non—small–cell lung cancer

F. Fossella, 2000, Current oncology reports.

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane‐refractory/resistant nonsmall cell lung carcinoma

Edward S. Kim, F. Khuri, K. Pisters, 2005, Cancer.

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.

S Lippman, S. Lippman, R. Perez-soler, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.

N. Hanna, K. Kelly, P. Bunn, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first‐line treatment of advanced nonsmall cell lung carcinoma (TAX 326)

F. Fossella, C. Belani, 2005, Cancer.

Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer.

C. Stevens, R. Komaki, Z. Liao, 2002, International journal of radiation oncology, biology, physics.

A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report.

R. Komaki, J. Cox, F. Fossella, 1998, International journal of radiation oncology, biology, physics.

Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06.

W. Curran, S. McDonald, R. Komaki, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

277 Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy

J. Roth, S. Swisher, A. Tsao, 2020, Journal for ImmunoTherapy of Cancer.

Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

A. Tsao, D. Gibbons, F. Fossella, 2021, JCO precision oncology.

Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer.

P. Thall, D. Gomez, Steven H. Lin, 2022, Cancer treatment and research communications.

A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors.

S. Lippman, W. Hong, F. Fossella, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors

R. Herbst, M. Truong, F. Fossella, 2004, Cancer Chemotherapy and Pharmacology.

Lymph node micrometastases in non small-cell lung cancer: clinical applications.

F. Fossella, N. Ordóñez, J. H. Perez-Cardona, 2000, Clinical lung cancer.

Small cell lung cancer clinical practice guidelines in oncology.

D. Ettinger, J. Crawford, F. Fossella, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.

J. Gu, F. Khuri, W. Hong, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and Stage IV non-small cell lung cancer

R. Figlin, K. Pisters, F. Fossella, 1998, Investigational New Drugs.

ZD1839 (Iressa) in non-small-cell lung cancer.

F. Khuri, R. Herbst, K. Pisters, 2002, Clinical lung cancer.

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.

S. Lippman, F. Fossella, D. Shin, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC.

F. Fossella, C. Lathia, M. Reck, 2011, Cancer biomarkers : section A of Disease markers.

Oncodiagnosis panel: 1999. Cancer of the lung: oncodiagnosis.

W. Travis, R. Komaki, F. Fossella, 2001, Radiographics : a review publication of the Radiological Society of North America, Inc.

Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.

J. Lee, S. Swisher, F. Fossella, 2017, Lung cancer.

OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)

A. Tsao, D. Gibbons, J. Kurie, 2018, Journal of Thoracic Oncology.

Adenocarcinoma of the lung in young patients

M. Spitz, F. Khuri, F. Fossella, 2000, Cancer.

Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer.

F. Fossella, R. Rosell, L. Milas, 2002, Lung cancer.

Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04.

D. Ettinger, W. Curran, P. Rubin, 1997, International journal of radiation oncology, biology, physics.

Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC

Joe Y. Chang, P. Thall, Steven H. Lin, 2020 .

Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.

W. Curran, H. Choy, R. Herbst, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non–Small Cell Lung Cancer

I. Wistuba, J. Lee, S. Swisher, 2020, Clinical Cancer Research.

The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens.

J. Rigas, F. Fossella, 1999, Seminars in oncology.

Targeted molecules in small cell lung cancer.

R. Salgia, F. Fossella, N. Murray, 2004, Seminars in oncology.

A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.

R. Komaki, J. Kurie, K. Pisters, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Docetaxel in second-line treatment of non-small-cell lung cancer.

F. Fossella, 2002, Clinical lung cancer.

Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy.

Joe Y. Chang, M. Spitz, Xifeng Wu, 2005, Seminars in oncology.

Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer.

Joe Y. Chang, S. Shirvani, R. Komaki, 2012, International journal of radiation oncology, biology, physics.

Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study.

R. Komaki, R. Perez-soler, J. Kurie, 1998, International journal of radiation oncology, biology, physics.

Phase II trial of recombinant IFN-α2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer

F. Khuri, F. Fossella, J. S. Lee, 1998 .

THE MANAGEMENT OF SUPERIOR SULCUS TUMORS

W. Hong, J. Roth, C. Stevens, 2001 .

Longitudinal associations between caregiver burden and patient and spouse distress in couples coping with lung cancer

K. Pisters, F. Fossella, H. Badr, 2013, Supportive Care in Cancer.

Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center.

J. Roth, R. Komaki, J. Cox, 2000, International journal of radiation oncology, biology, physics.

Comparison of Docetaxel- and Vinca Alkaloid–Based Chemotherapy in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of Seven Randomized Clinical Trials

V. Georgoulias, F. Fossella, S. Laporte, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

N. Ajami, Jing Wang, I. Wistuba, 2023, Nature Medicine.

Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

J. Roth, R. Komaki, E. Atkinson, 1998, Lung cancer.

Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer.

W. Hong, R. Herbst, R. Komaki, 2009, International journal of radiation oncology, biology, physics.

Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma

W. Hong, R. Perez-soler, F. Fossella, 1998, Cancer.

Phase II Study of Intravenous Doxil® in Malignant Pleural Mesothelioma

R. Perez-soler, M. Truong, J. Kurie, 2000, Investigational New Drugs.

P-452 Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender

R. Ramlau, F. Fossella, M. Millward, 2005 .

A Phase I Clinical Trial of Thoracic Radiotherapy and Concurrent Celecoxib for Patients with Unfavorable Performance Status Inoperable/Unresectable Non–Small Cell Lung Cancer

Joe Y. Chang, T. Guerrero, R. Komaki, 2005, Clinical Cancer Research.

Integration of Remote Symptom and Biometric Monitoring Into the Care of Adult Patients With Cancer Receiving Chemotherapy-A Decentralized Feasibility Pilot Study.

F. Fossella, M. Overman, S. Peterson, 2023, JCO oncology practice.

Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study.

J. Lee, S. Swisher, A. Tsao, 2021 .

B3-07: A phase II study of Cetuximab (C225) in combination with chemoradiation

W. Curran, H. Choy, R. Komaki, 2007 .

Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC)

Diane D. Liu, G. Gladish, S. Lippman, 2007 .

Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall‐cell lung cancer

Edward S. Kim, Diane D. Liu, G. Gladish, 2010, Cancer.

APhase IClinicalTrial ofThoracic Radiotherapy and Concurrent Celecoxib for Patientswith Unfavorable Performance Status Inoperable/Unresectable Non^Small Cell Lung Cancer

Joe Y. Chang, Z. Liao, J. Cox, 2005 .

Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials

M. Buyse, J. Pignon, V. Georgoulias, 2013, BMJ Open.

Bortezomib ± docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): A phase 2 study

R. Govindan, D. Carbone, F. Fossella, 2005 .

Lung Cancer Patients and Their Spouses: Psychological and Relationship Functioning Within 1 Month of Treatment Initiation

Hoda Badr, L. Schover, K. Pisters, 2008, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

510 POSTER Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumours

F. Fossella, P. Lorigan, P. Woll, 2008 .

Pemetrexed in advanced NSCLC: a review of the clinical data.

R. Herbst, F. Fossella, R. Zinner, 2004, Oncology.

Abstract B237: Clinical experience of IMGN901 (BB‐10901, huN901‐DM1) in patients with Merkel cell carcinoma (MCC)

F. Fossella, P. Lorigan, P. Woll, 2009 .

Efficacy results from a phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors.

L. C. Chen, F. Fossella, P. Lorigan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer

F. Meric-Bernstam, F. Fossella, A. Naing, 2023, Cancer.

Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC).

J. Roth, J. Lee, S. Swisher, 2017 .

Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report.

F. Khuri, R. Komaki, K. Pisters, 1997, Seminars in oncology.

OA13.06 Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer - NEOSTAR Study

J. Roth, S. Swisher, A. Tsao, 2019, Journal of Thoracic Oncology.

O-5 Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC)

N. Hanna, P. Bunn, F. Shepherd, 2003 .

Phase I trials of pemetrexed.

U. Gatzemeier, F. Fossella, 2002, Seminars in oncology.

1012P Resistance mechanisms to dual EGFR and MET inhibition in patients with EGFR-mutant MET-amplified non-small cell lung cancer

A. Tsao, F. Fossella, A. Vaporciyan, 2022, Annals of Oncology.

Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer.

Radhe Mohan, Daniel Gomez, James D. Cox, 2016 .

A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (pts) with stage III A/B non-small cell lung cancer (NSCLC): An interim report of the RTOG 0324 trial

W. Curran, H. Choy, R. Komaki, 2005 .

Prognostic Value of Positron Emission Tomography/Computed Tomography Findings in Limited-stage Small Cell Lung Cancer Before Chemoradiation Therapy

G. Gladish, D. Gomez, R. Komaki, 2014, American journal of clinical oncology.

MA09.03 Identification of Mechanisms of Acquired Resistance to Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)

A. Tsao, Limei Hu, D. Gibbons, 2019, Journal of Thoracic Oncology.

Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial

Joe Y. Chang, I. Wistuba, S. Swisher, 2023, The Lancet.

Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Preliminary results.

K. Kelly, F. Fossella, J. Schiller, 2004, Journal of Clinical Oncology.

Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP.

F. Fossella, W. Fordyce, L. Kasi, 1993, Nuclear medicine and biology.

A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC).

C. Obasaju, R. Herbst, K. Pisters, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

937 Phase I trial of GL331, a novel topoisomerase-II (T-II) inhibitor for advanced refractory cancer

F. Fossella, R. Newman, K. Gorelick, 1995 .

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

J. Roth, E. Atkinson, F. Fossella, 1994, Journal of the National Cancer Institute.

Implementation of Multidisciplinary Care in the Treatment of Patients with Lung Cancer

R. Komaki, F. Fossella, J. Putnam, 2003 .

Neoadjuvant chemotherapy in stage Illa non-small cell lung cancer LEARNING POINTS *

R. Komaki, E. Atkinson, A. Ariza, 2022 .

Plasma biomarkers in a phase II trial of sorafenib in advanced non-small cell lung cancer

U. Gatzemeier, F. Fossella, J. Elting, 2007 .

O-71 Hyperfractionated and accelerated thoracic radiation therapy (HFXA/TRT) increased survival compared to daily TRT for limited small cell lung cancer (LSCLC) patients treated with concurrent chemotherapy

R. Herbst, C. Stevens, R. Komaki, 2003 .

Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non–Small Cell Lung Cancer

F. Fossella, E. Waxman, 2016, Journal of the advanced practitioner in oncology.

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.

G. Scagliotti, N. Hanna, F. Shepherd, 2009, The oncologist.

Systemic treatment of non-small-cell lung cancer.

F. Fossella, R. Lenzi, J. Lee, 1992, Comprehensive therapy.

Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures: An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung Cancer

F. de Marinis, M. Salzberg, J. Jassem, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I studies of gemcitabine

S. Lippman, F. Fossella, J. Abbruzzese, 1993 .